Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07066657 · ClinicalTrials.gov registry record · Phase 1
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
A Phase 1 study of Colorectal Cancer and Pancreatic Cancer, sponsored by ArriVent BioPharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 405
- Enrollment target
- 15
- Study locations
NCT07066657 is a Phase 1 study of Colorectal Cancer and Pancreatic Cancer that is actively recruiting participants, run by ArriVent BioPharma. The registered enrollment target is 405 participants, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (73% lower). The trial reports 15 study locations across 11 states.
The verdict
NCT07066657, a Phase 1 study of Colorectal Cancer and Pancreatic Cancer, is actively recruiting participants, sponsored by ArriVent BioPharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 405 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG MRG007
Study Locations (15)
California
- ULCA - Los Angeles
- UCSF - San Francisco
Colorado
- University of Colorado - Aurora
- Sarah Cannon Research Institute - Denver
Texas
- MD Anderson Cancer Center - Houston
- NEXT Dallas - Irving
Shanghai Municipality
- Renji Hospital Shanghai Jiaotong University School of Medicine - Shanghai
- Zhongshan Hospital Fudan University - Shanghai
Florida
- Sarah Cannon Research Institute - Sarasota
Tennessee
- Sarah Cannon Research Institute - Nashville
Virginia
- NEXT Virginia - Fairfax
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2025-07-25 |
| Est. Completion | 2030-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07066657
The ClinicalTrials.gov registry entry for NCT07066657 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 405 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (73% lower). The listed sponsor is ArriVent BioPharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRG007 is the first listed.
NCT07066657 reports 15 study locations spanning 11 distinct geographic areas - top geographies include California, Colorado, Texas.
Frequently Asked Questions
What is clinical trial NCT07066657 about?
NCT07066657 is a clinical study titled "A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors". This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
What is the current status of trial NCT07066657?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 405 participants. The study started on 2025-07-25. Estimated completion is 2030-12.
What conditions does trial NCT07066657 study?
This clinical trial studies the following conditions: Colorectal Cancer, Pancreatic Cancer, Gastric Cancer, Locally Advanced or Metastatic Solid Tumors.
What interventions are being tested in trial NCT07066657?
The interventions under investigation include: MRG007 (DRUG).
Who is sponsoring clinical trial NCT07066657?
This trial is sponsored by ArriVent BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07066657 being conducted?
This trial has 15 study locations across California, Colorado, Florida, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.